TB-500 (Thymosin Beta-4)
Also known as: TB-500, TB500, Thymosin Beta-4, TB4, Thymosin Beta 4
Synthetic fragment of thymosin beta-4, used for tendon and soft-tissue injuries — plausible mechanism, animal data, and essentially no controlled human evidence.
Substance family
Peptides used for tendon, gut and skin repair. Mechanisms are described and animal data exists; controlled human trials for these applications largely do not.
Effects on
Which outcomes this substance acts on — descriptive, not a recommendation.
Strain profile
Where this substance is most likely to hit — a rough orientation, individually dependent on dose, duration and predisposition.
This substance works against
Dosing & protocols by goal
Rough orientation ranges as reported in harm-reduction literature — not an individual treatment plan. Doses are individual and open-ended; frequency depends on the ester or half-life.
Acute injury — loading phase
ExperimentalDose
2–2.5 mg / week
Frequency
Split into 2 doses
Cycle length
4–6 weeks
Common practice in the peptidepeptideA short chain of amino acids — the reason this whole category has to be injected. scene, not an established protocol. Dose in mg, unlike most peptides — a point where confusion with µg substances happens.
Maintenance after the loading phase
ExperimentalDose
2–2.5 mg / month
Frequency
1× / week to 1× / month
Cycle length
Varies
Reported as maintenance dosing. There is no data establishing whether this achieves anything.
Medical use
MedicalDose
—
Frequency
—
Cycle length
—
No approved indication anywhere. Human trials exist for eye and heart conditions, but none support the applications described here.
Side effect & countermeasure
Typical problems and what you can do to reduce harm — at a glance. Does not replace medical monitoring.
Problem
No controlled human evidence for the intended use
Countermeasure
The mechanism is plausible and the animal data real, but neither substitutes for human trials. Anyone using it should understand they are relying on mechanism and anecdote, not evidence. That does not make it useless — it makes the expected benefit uncertain.
Problem
Theoretical concern about tumour growth
Countermeasure
Thymosin beta-4 promotes angiogenesis and cell migration — the same processes tumours use to grow and spread. This has not been demonstrated as a clinical risk in humans, but existing or suspected malignancy is a clear reason not to use it.
Problem
Masking of an injury that has not healed
Countermeasure
If pain decreases while the structure is still damaged, the risk of a worse re-injury rises. Do not increase training loads on symptom relief alone; a tendon needs time regardless of what accelerates it.
Problem
Uncertain product quality
Countermeasure
Only vendors with an independent HPLC/MS analysis certificate. Reconstitute with bacteriostatic water, store refrigerated, observe the shelf life after reconstitution.
Problem
Dosing confusion between mg and µg
Countermeasure
TB-500 is dosed in milligrams while most peptidespeptidesA short chain of amino acids — the reason this whole category has to be injected. in this field use micrograms. Transferring a µg-based habit here underdoses by a factor of 1000 — check the vial label and calculate the concentration before the first injection.
Overview
TB-500 is a synthetic fragment of thymosin beta-4, a protein that occurs naturally in nearly all human cells and plays a role in wound healing and cell migration.
In the rehab and peptide scene it is used for tendon, ligament and muscle injuries. The honest position on this substance requires stating clearly what exists and what does not: the mechanism is well described, animal studies show effects on wound healing, and controlled human trials for this application do not exist.
Mechanism of Action
Thymosin beta-4 binds actin, one of the fundamental structural proteins of the cell. Through this it influences cell migration — the ability of cells to move to a site of injury — and promotes the formation of new blood vessels.
Both processes are central to healing. Damaged tissue needs cells that reach it and blood vessels that supply them. This is the basis of the assumption that TB-500 accelerates healing of tendon and soft-tissue injuries.
The same properties are the source of the theoretical concern. Angiogenesis and cell migration are exactly what tumours require to grow and metastasise. This has not been demonstrated as a clinical risk in humans, but it is the reason an existing or suspected malignancy rules the substance out.
One practical detail causes real problems: TB-500 is dosed in milligrams, while BPC-157, ipamorelin and most other peptides in this field are dosed in micrograms. Anyone carrying over a habit from those underdoses by a factor of a thousand.
Typical Context
TB-500 is used after tendon, ligament or muscle injuries, often alongside BPC-157, since the two are attributed complementary mechanisms. A loading phase of four to six weeks at two to two and a half milligrams weekly is the commonly reported pattern, followed by lower maintenance dosing.
None of this rests on trial data. It rests on mechanism, animal studies and accumulated user reports — which is worth knowing before spending money on it.
A second point matters more than the dosing question. If a peptide reduces pain while the underlying structure is still damaged, the temptation is to train harder sooner. Tendons adapt slowly regardless of what supports the process. Reduced pain is not evidence of a healed structure, and treating it as such is how a manageable injury becomes a serious one.
Side Effects & Risks
- No controlled human evidence for this application
- Theoretical concern regarding growth of existing tumours
- Masking of pain in an injury that has not healed
- Local reactions at the injection site
- Fatigue, headache — reported occasionally
- Uncertain product quality on the grey market
Blood Work & Monitoring
There is no specific marker for TB-500. What remains sensible is a baseline panel before starting, so that any changes can be attributed:
- Complete blood count
- Liver values (ALT, AST, GGT)
- Kidney values (creatinine, cystatin C)
Harm-Reduction Notes
- Dose in mg, not µg — check the vial and calculate the concentration before the first injection
- Existing or suspected malignancy is a clear contraindication
- Do not increase training loads on reduced pain alone; the structure needs its time
- Only sources with an independent analysis certificate
- Reconstitute with bacteriostatic water, store refrigerated, observe shelf life
- Understand what you are buying: mechanism and anecdote, not clinical evidence
Legal status by region
Regulation differs considerably between jurisdictions and changes over time. This is a rough orientation, not legal advice — check the rules that apply where you are.
| Region | Regulatory status |
|---|---|
| United States | Not approved for human useSold as a research chemical; marketing for human consumption is unlawful. |
| EU / UK | No marketing authorisationNeither a medicine nor a supplement — no legal route for human use. |
| Most other jurisdictions | Unregulated grey areaPossession is legal in many places precisely because no framework covers it. That is not an indication of safety. |
| Competitive sport | ProhibitedListed by WADA where a relevant class applies. |